They will come to inspect after the horse has bolted from the stable,” grumbles a visibly miffed Kiran Mazumdar-Shaw. The chairman and managing director of Biocon is seated in her tastefully decorated meeting room at the Bengaluru headquarters, where the walls are adorned with paintings by Scottish artist Tom Robertson and bright sunlight pours in through the large windows. The Watson & Creek meeting room is named after the Nobel laureates who discovered DNA; in fact, all meeting rooms at India’s largest biotech firm are named after Nobel Prize winning scientists. This is just another sign that Biocon takes its research seriously, the biggest indicator, of course, being that like most other large Indian pharmas, it is working at breakneck speed to be the first to launch an Indian blockbuster drug. And that explains why Mazumdar-Shaw is unhappy.
Drug majors are shifting clinical trials out of India as lawmakers turn on the heat
Kiran Mazumdar-Shaw|Biocon|Merck Sharp & Dohme|GSK|Swasthya Adhikar Manch|Drugs and Cosmetics Act|Swati Piramal|Piramal Enterprises|Ranjit Roy Chaudhury|Roy Chaudhary committee|New Drug Advisory Committees|Jamila Joseph|Reliance Life Sciences|Ranjit Shahani|Novartis India|Shoibal Mukherjee|Quintiles|Dr Reddy’s Laboratories|Sun Pharma|KV Subramaniam|Suneela Thatte|Saurendra Das|Excel Life Sciences
Summer wine and salad
Kishore Singh - January 19, 2015
The million-dollar question: Is investing a game of luck or skill?
Shankar Sharma - May 04, 2021
Every crisis is an opportunity, if you are on the right side of equities
Samir Arora - May 04, 2021
Viraj Mehta trusts the toughness and bounce of a company that has seen many trials
Viraj Mehta - May 04, 2021
Safir Anand spots a mid-sized company with the right chemistry and catalytic circumstances
Safir Anand - May 07, 2021